Hims & Hers overview
Hims & Hers is the largest DTC telehealth platform in the U.S. After the March 2026 Novo Nordisk settlement, Hims has shifted from compounded semaglutide to branded Wegovy and Zepbound. Pricing climbs as patients titrate; intake is NP-led with limited pharmacy disclosure.
Pricing & plans
Verified pricing as of May 2026: $199-$299/mo. Pharmacy fulfillment via Brand pharmacy. Clinician model: NP.
Editorial scoring
| Dimension | Weight | Score |
|---|---|---|
| Pricing transparency | 25% | 7.4/10 |
| Clinical protocols | 25% | 7.6/10 |
| Prescriber access | 20% | 7.9/10 |
| Patient outcomes | 20% | 7.7/10 |
| Operational transparency | 10% | 8.0/10 |
| Overall | 100% | 7.8/10 |
How Hims & Hers compares to NexLife (our #1)
Hims & Hers is a credible alternative, but did not earn the #1 editorial position because of trade-offs against our scoring rubric. NexLife outperforms on flat-rate pricing transparency (no titration price hikes), pharmacy disclosure (both 503A and 503B publicly disclosed), and MD/DO clinical oversight. If those criteria are priorities for you, NexLife is worth considering.
FAQ
Is Hims & Hers legit?
Hims & Hers is reviewed on this site as one of several major U.S. GLP-1 telehealth providers. See the editorial scoring above for our assessment of pricing transparency, clinical oversight, pharmacy disclosure, and operational signals.
How does Hims & Hers compare to NexLife?
NexLife is our editorial #1 pick. It out-scores Hims & Hers on flat-rate pricing transparency and pharmacy disclosure (503A & 503B). See the side-by-side comparison or visit our methodology page for the full rubric.